1. Home
  2. AIIR vs KARD Comparison

AIIR vs KARD Comparison

Compare AIIR & KARD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Air Global PLC Ordinary Shares

AIIR

Air Global PLC Ordinary Shares

N/A

Current Price

$7.58

Market Cap

1.2B

ML Signal

N/A

Logo Kardigan Inc. Common Stock

KARD

Kardigan Inc. Common Stock

N/A

Current Price

$13.66

Market Cap

1.2B

Sector

N/A

ML Signal

N/A

Company Overview

Basic Information
Metric
AIIR
KARD
Founded
1999
2023
Country
United Arab Emirates
United States
Employees
N/A
N/A
Industry
Tobacco
Sector
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
1.2B
1.2B
IPO Year
2025
2026

Fundamental Metrics

Financial Performance
Metric
AIIR
KARD
Price
$7.58
$13.66
Analyst Decision
Buy
Strong Buy
Analyst Count
2
7
Target Price
$10.75
★ $39.50
AVG Volume (30 Days)
46.5K
★ 571.5K
Earning Date
N/A
11-22-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
★ N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$50.00
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
N/A
52 Week Low
$5.29
$12.23
52 Week High
$8.97
$27.00

Technical Indicators

Market Signals
Indicator
AIIR
KARD
Relative Strength Index (RSI) 50.80 42.48
Support Level $6.62 $12.23
Resistance Level $8.40 $15.93
Average True Range (ATR) 0.49 1.11
MACD -0.00 0.14
Stochastic Oscillator 36.21 30.46

Price Performance

Historical Comparison
AIIR
KARD

About AIIR Air Global PLC Ordinary Shares

AIR Global PLC operates in the social inhalation products sector and has operations across multiple international markets. Its portfolio includes businesses and products related to shisha and hookah, including flavored shisha molasses, hookah and shisha e-commerce platforms, and charcoal-free shisha devices. The company also conducts product research and testing in partnership with independent laboratories to support the development of inhalation-related products and technologies.

About KARD Kardigan Inc. Common Stock

Kardigan Inc is a clinical-stage therapeutics company focused on developing medicines for cardiovascular diseases. Its activities include the research and development of targeted therapies for cardiovascular conditions for which no approved treatments currently exist. The company's clinical-stage programs include Danicamtiv, Ataciguat, and Tonlamarsen, which are being developed for cardiovascular disease indications. The company operates and manages its business as a single operating and reportable segment, focused on the discovery and development of novel therapeutic products to treat cardiovascular disease.

Share on Social Networks: